Overview

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Status:
Completed

Trial end date:
2017-09-07

Target enrollment:

Participant gender:

Summary

To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Sunitinib